Inhibition of PCSK9: A powerful weapon for achieving ideal LDL cholesterol levels
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
lasma LDL cholesterol level is a major determinant of cardiovascular disease (CVD) risk.The striking results of the early large-scale statin trials showed that LDL levels can be reduced by 30-40% with comparable percentage reductions in CVD risk.More recent trials show that there is progressively greater relative risk reduction as the on-treatment level of LDL drops.In the JUPITER trial (1), rosuvastatin treatment of healthy subjects who had elevated CRP levels lowered LDL cholesterol levels Ϸ50% [from a baseline median of 108 mg/dL to 55 mg/dL (25% had values Ͻ44 mg/ dL)] and resulted in a Ϸ50% reduction in all CVD events.We recently suggested that an ''ideal'' LDL cholesterol level of 50 mg/dL should be the target goal of therapy in all high-risk subjects (2), but the Jupiter trial extends this concept to an even larger population and supports the concept that ''the lower the LDL the better'' is a reasonable position.However, achieving LDL levels of 50 mg/dL or even lower in patients with high initial values is often not possible with statins alone, even with maximum dosages.Such patients often require 2 or even 3 different drugs to reach a LDL level Ͻ100 mg/dL, much less 50 mg/dL, and such combinations increase the risk of side effects.Consequently, the search for new cholesterol-lowering interventions continues apace.In this issue of PNAS, Chan et al. (3) describe dramatic cholesterol lowering in nonhuman primates with the use of a mAb against proprotein convertase subtilisin/ kexin type 9 (PCSK9), a recently described key regulator of hepatocyte LDL receptor (LDL-R) expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide
Shan, L., Pang, L., Zhang, R., Murgolo, N. J., Lan, H., & Hedrick, J. A. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.106 · Cited by 180
Duff, C. J., Scott, M. J., Kirby, I. T., Hutchinson, S. E., Martin, S. L., & Hooper, N. M. (2009) · Biochemical Journal · doi:10.1042/bj20082407 · Cited by 99
Cited by
ATUALIZAÇÃO DA DIRETRIZ BRASILEIRA DE DISLIPIDEMIAS E PREVENÇÃO DA ATEROSCLEROSE - 2017
Faludi, A., Izar, M., Saraiva, J., Chacra, A., Bianco, H., Afiune Neto, A., Bertolami, A., Pereira, A., Lottenberg, A., Sposito, A., et al. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170121 · Cited by 633
V Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose
Xavier, H. T., Izar, M. C., Faria Neto, J. R., Assad, M. H., Rocha, V. Z., Sposito, A. C., Fonseca, F. A., Santos, J. E. D., Santos, R. D., Bertolami, M. C., et al. (2013) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.2013s010 · Cited by 454
PCSK9 is a critical regulator of the innate immune response and septic shock outcome
Walley, K. R., Thain, K. R., Russell, J. A., Reilly, M. P., Meyer, N. J., Ferguson, J. F., Christie, J. D., Nakada, T.-A., Fjell, C. D., Thair, S. A., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008782 · Cited by 355
Görgüç, A., Gençdağ, E., & Yılmaz, F. M. (2020) · Food Research International · doi:10.1016/j.foodres.2020.109504 · Cited by 312
Wadhera, R. K., Steen, D. L., Khan, I., Giugliano, R. P., & Foody, J. M. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.11.010 · Cited by 306
“The significance of the chronicity of LDL-C exposure is also supported by recent epidemiologic analyses, which suggest that strategies for earlier initiation and prolonged LDL-C lowering might yield striking benefits for reducing CV risk.(36,37) The association of LDL with CV risk is also supported by data from altern…”
Method
Metadata
- Authors
- Steinberg, D., & Witztum, J. L.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2009-06-16
- Volume
- 106
- Issue
- 24
- Pages
- 9546-9547
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2028004589
- Cited by
- 107
- References
- 6
- FWCI
- 7.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of PCSK9: A powerful weapon for achieving ideal LDL cholesterol levels. https://app.cochat.ai/papers/10.1073/pnas.0904560106
- The paper
- Steinberg, D., & Witztum, J. L. (2009). Inhibition of PCSK9: A powerful weapon for achieving ideal LDL cholesterol levels. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0904560106
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.